HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Abstract
DNA vaccines provide an attractive technology platform against bioterrorism agents due to their safety record in humans and ease of construction, testing, and manufacture. We have designed monovalent and bivalent anthrax plasmid DNA (pDNA) vaccines encoding genetically detoxified protective antigen (PA) and lethal factor (LF) proteins and tested their immunogenicity and ability to protect rabbits from an aerosolized inhalation spore challenge. Immune responses after two or three injections of cationic lipid-formulated PA, PA plus LF, or LF pDNAs were at least equivalent to two doses of anthrax vaccine adsorbed (AVA). High titers of anti-PA, anti-LF, and neutralizing antibody to lethal toxin (Letx) were achieved in all rabbits. Eight or nine animals in each group were challenged with 100x LD(50) of aerosolized anthrax spores 5 or 9 weeks after vaccination. An additional 10 animals vaccinated with PA pDNA were challenged >7 months postvaccination. All animals receiving PA or PA plus LF pDNA vaccines were protected. In addition, 5 of 9 animals receiving LF pDNA survived, and the time to death was significantly delayed in the others. Groups receiving three immunizations with PA or PA plus LF pDNA showed no increase in anti-PA, anti-LF, or Letx neutralizing antibody titers postchallenge, suggesting little or no spore germination. In contrast, titer increases were seen in AVA animals, and in surviving animals vaccinated with LF pDNA alone. Preclinical evaluation of this cationic lipid-formulated bivalent PA and LF vaccine is complete, and the vaccine has received U.S. Food and Drug Administration Investigational New Drug allowance.
AuthorsG Hermanson, V Whitlow, S Parker, K Tonsky, D Rusalov, M Ferrari, P Lalor, M Komai, R Mere, M Bell, K Brenneman, A Mateczun, T Evans, D Kaslow, D Galloway, P Hobart
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 101 Issue 37 Pg. 13601-6 (Sep 14 2004) ISSN: 0027-8424 [Print] United States
PMID15342913 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Aerosols
  • Anthrax Vaccines
  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Toxins
  • Cations
  • Lipids
  • Vaccines, DNA
  • anthrax toxin
Topics
  • Aerosols
  • Animals
  • Anthrax (immunology, prevention & control)
  • Anthrax Vaccines (chemistry, genetics, immunology)
  • Antibodies, Bacterial (immunology)
  • Antigens, Bacterial (genetics, immunology)
  • Bacillus anthracis (immunology)
  • Bacterial Toxins (genetics, immunology)
  • Cations (chemistry)
  • Gene Expression
  • Inhalation
  • Lipids (chemistry)
  • Molecular Sequence Data
  • Plasmids (genetics)
  • Rabbits
  • Spores, Bacterial (immunology)
  • Vaccination
  • Vaccines, DNA (chemistry, genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: